Positive results in uPAR-PET/MR Phase II study in brain cancer: Curasight

Posted on by

uPAR-PET with 68Ga-NOTA-AE105 (now known as uTRACE®) was highly prognostic both regarding progression-free survival and overall survival. 94% of glioblastomas (WHO grade 4 gliomas) in the study were uPAR-PET positive underlines validity of using this target for improved diagnosis and…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.